Series of three cases with basal cell carcinoma on the back of the nose treated with HeberFERON®

Abstract

Introduction: the high incidence of skin cancer in the world –specifically basal cell carcinoma–, and the aesthetic and functional sequelae derived from its surgical intervention, motivate the search for other less invasive treatments. HeberFERON®, still in phase IV of clinical trial, is part of the Cuban drug table and becomes a valid alternative.

Objective: to present a series of three patients diagnosed with basal cell carcinoma on the back of the nose in which the treatment was effective.

Cases presentation: all three patients underwent initial dermoscopy, with a diagnostic impression of basal cell carcinoma. Histological examination confirmed the disease. HeberFERON® injections were administered three times a week, every other day for three consecutive weeks. The routes of administration were perilesional, (intradermal) and intramuscular. All were cured after 16 weeks in which the evolution of their treated lesions was followed.

Conclusions: the effectiveness of HeberFERON® treatment in a series of three patients diagnosed with basal cell carcinoma on the dorsum of the nose is shown. The main adverse reactions were edema and erythema at the infiltration site. The contribution of this study is based on showing HeberFERON® as a novel therapeutic option to avoid mutilation in the h zone of the face, which makes its use recommended in cases such as those presented